EUVIMEDEUVIMED entdecken
Crossref

From undruggable to actionable: advances in KRAS targeting in colorectal cancer

Mei Chan, Meghna Shelke, Amanda Townsend, Amitesh Roy, Vy Broadbridge, Christos Karapetis, Timothy Price

Academia Oncology · 06.04.2026 · 3 (1)

DOI: 10.20935/acadonco8216 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Academia Oncology, online erschienen am 06.04.2026. Verfasst von Mei Chan und 6 weiteren Autor:innen. Die Arbeit nennt 95 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

KRAS (Kristen rat sarcoma viral oncogene homolog) mutations occur in approximately 40–50% of metastatic colorectal cancer (CRC) cases and have long been associated with resistance to anti-epidermal growth factor receptor (EGFR) therapies and poor clinical outcomes. Historically considered “undruggable”, KRAS has recently become a viable therapeutic target following the development of allele-specific inhibitors. The approval of KRAS G12C inhibitors such as sotorasib and adagrasib represents a major milestone, demonstrating clinical activity and improved outcomes compared with standard therapies in the molecularly defined subset. However, single-agent activity remains modest in CRC due to adaptive resistance mechanisms, including compensatory activation of EGFR and downstream signalling pathways. Combination strategies, particularly co-targeting of EGFR and KRAS G12C, have shown enhanced efficacy and are redefining treatment paradigms. Beyond G12C, newer approaches aim to broaden therapeutic coverage through next-generation KRAS inhibitors, pan-RAS or RAS(ON) inhibitors, and allele-specific agents targeting KRAS G12D and KRAS G12V. Additional strategies incorporating Src homology region 2-containing protein tyrosine phosphatase-2 (SHP2), son of sevenless homolog 1 (SOS1), or mitogen-activated protein kinase (MEK) inhibition, as well as emerging immune-based therapies, hold promise in overcoming resistance and improving durability of response. This review summarises recent advances in targeting KRAS-mutant CRC, explores mechanisms of therapeutic resistance, and highlights ongoing efforts to expand precision-based strategies across diverse KRAS alterations.

Zitieren

APA

Chan, M., Shelke, M., Townsend, A., Roy, A., Broadbridge, V., Karapetis, C., & Price, T. (2026). From undruggable to actionable: advances in KRAS targeting in colorectal cancer. Academia Oncology, 3(1). https://doi.org/10.20935/acadonco8216

Vancouver

Chan M, Shelke M, Townsend A, Roy A, Broadbridge V, Karapetis C, et al. From undruggable to actionable: advances in KRAS targeting in colorectal cancer. Academia Oncology. 2026;3(1). doi:10.20935/acadonco8216

BibTeX
@article{Chan2026,
  author = {Chan, Mei and Shelke, Meghna and Townsend, Amanda and Roy, Amitesh and Broadbridge, Vy and Karapetis, Christos and Price, Timothy},
  title = {From undruggable to actionable: advances in KRAS targeting in colorectal cancer},
  journal = {Academia Oncology},
  year = {2026},
  volume = {3},
  number = {1},
  doi = {10.20935/acadonco8216}
}
Kostenlos starten →